Literature DB >> 27067008

[Current state of treatment strategies for atrial fibrillation].

C Rogge1, S Hilbert1, N Dagres1, G Hindricks2.   

Abstract

Atrial fibrillation is the most common form of persistent cardiac arrhythmia with a greatly increasing prevalence due to an aging population and increasing cardiovascular risk factors. Apart from impairment of the quality of life atrial fibrillation is associated with a high morbidity, most importantly stroke and heart failure. The therapy is complex and aims at improving symptoms as well as the prevention of thromboembolic complications, heart failure and aggravating comorbidities. Based on individual patient characteristics and symptoms therapy is mainly based on heart rate control by pharmacological means or therapy for maintaining sinus rhythm. This treatment includes antiarrhythmic drugs and catheter ablation. Current research is aimed at the investigation of the electrophysiological mechanisms of recurrent therapy refractive atrial fibrillation and the question whether the maintenance of sinus rhythm can improve the prognosis of atrial fibrillation.

Entities:  

Keywords:  Anticoagulants; Arrhythmogenic substrate analysis; Catheter ablation; Heart rate and rhythm control; Symptom based management

Mesh:

Substances:

Year:  2016        PMID: 27067008     DOI: 10.1007/s00059-016-4413-9

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  55 in total

1.  [Catheter ablation of persistent atrial fibrillation : pulmonary vein isolation, ablation of fractionated electrograms, stepwise approach or rotor ablation?].

Authors:  D Scherr
Journal:  Herz       Date:  2015-02       Impact factor: 1.443

2.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.

Authors:  Gregory Y H Lip; Lars Frison; Jonathan L Halperin; Deirdre A Lane
Journal:  J Am Coll Cardiol       Date:  2010-11-24       Impact factor: 24.094

3.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

4.  Biventricular pacing improves cardiac function and prevents further left atrial remodeling in patients with symptomatic atrial fibrillation after atrioventricular node ablation.

Authors:  Michael V Orlov; Julius M Gardin; Mara Slawsky; Renee L Bess; Gerald Cohen; William Bailey; Vance Plumb; Horst Flathmann; Katerina de Metz
Journal:  Am Heart J       Date:  2010-02       Impact factor: 4.749

Review 5.  Atrial fibrillation: mechanisms, therapeutics, and future directions.

Authors:  Jason Pellman; Farah Sheikh
Journal:  Compr Physiol       Date:  2015-04       Impact factor: 9.090

6.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Gregory Y H Lip; Jesper Lindhardsen; Deirdre A Lane; Ole Ahlehoff; Morten Lock Hansen; Jakob Raunsø; Janne Schurmann Tolstrup; Peter Riis Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal:  Thromb Haemost       Date:  2011-07-20       Impact factor: 5.249

7.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

8.  Nonfluoroscopic catheter visualization in atrial fibrillation ablation: experience from 375 consecutive procedures.

Authors:  Philipp Sommer; Sascha Rolf; Christopher Piorkowski; Thomas Gaspar; Yan Huo; Carlos Piedra; Sergio Richter; Andreas Bollmann; Arash Arya; Gerhard Hindricks
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-07-19

Review 9.  Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review.

Authors:  Amit Noheria; Abhishek Kumar; John V Wylie; Mark E Josephson
Journal:  Arch Intern Med       Date:  2008-03-24

10.  Characterization of Electrograms from Multipolar Diagnostic Catheters during Atrial Fibrillation.

Authors:  Prasanth Ganesan; Elizabeth M Cherry; Arkady M Pertsov; Behnaz Ghoraani
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.